Many cardiovascular side-effects have been reported following the administration of naloxone in patients with pre-existent cardiovascular disease. l . 3 We wish to report one death in which pulmonary oedema and subsequent cardiac arrest followed the administration of intravenous naloxone in a previously healthy young man. CASE REPORT The patient was a 27-year-old 54-kg male who was admitted to hospital following an alleged assault during which he sustained facial injuries. Momentary loss of consciousness was thought to have occurred.
Examination on admission revealed marked bilateral periorbital swelling with associated bruising. A full range of ocular movement was present. No diplopia was reported, but some blurring of vision was present on left lateral gaze. A fractured nose with no septal haematoma was noted. Neurological examination was normal except for bilateral diminished infra-orbital sensation. There was also surgical emphysema present on the left side of the face. Full range of neck movement was present, and there was no cervical tenderness.
Cardiovascular examination revealed no cardiomegaly or abnormal sounds. Blood pressure was 130/80 mmHg, pulse rate 100 bpm and regular, and the patient was afrebrile. The patient had no significant past medical history. He was a non-smoker on no medications with no elicited history of drug abuse. A history of bee-sting allergy was noted. Radiological examination of the skull was normal, and a facial series revealed a Le Fort 11 fracture, a pyramidal fracture consisting of bilateral fractured zygomas, and a fractured nasal bone. Chest X-ray was not performed as the chest examination had been normal. Serum electrolytes were normal except for a serum potassium of 3.4 mM/I (normal 3.5-5.0 mM/I).
Faciomaxillary assessment on the day of admission determined that reduction and stabilisation of the facial fractures would require a Levant frame in addition to intraoral fixation under general anaesthesia. It was decided that this surgery should be performed after the facial swelling had subsided sufficiently.
Four days after admission the patient was taken to the operating theatre for surgery. Premedication of pethidine 50 mg and promethazine 25 mg was given intramuscularly one hour before the induction of anaesthesia. An infusion of Hartmann's solution was commenced. Induction consisted of fentanyl 200 mcg and thiopentone 250 mg with 100 mg succinylcholine to facilitate intubation. This was performed easily, initially with a 7.0 RAE nasotracheal tube. The position of the tube was checked by auscultation and found to be correct. A throat pack was inserted. Anaesthesia was maintained with nitrous oxide 4 litres per minute, oxygen 2 litres per minute, and enflurane up to 1.5%. Muscle relaxation was achieved with alcuronium 15 mg. Monitoring consisted of an electrocardiogram and a Dinamap automated blood pressure machine. The blood pressure stabilised at 110/70 mmHg and the pulse at 85 beats per minute. The anaesthetic was uneventful and at all times the patient was well oxygenated and his vital signs were stable. Following the reduction and stabilisation of the maxillary fracture with a Levant frame, the nasotracheal tube was changed for an 8.0 RAE orotracheal tube. The nasal fracture was then reduced and stabilised. Droperidol 3 mg was given about 45 minutes before the termination of anaesthesia. The blood loss was minimal and the total volume of IV fluid infused was 1100 ml of Hartmann's Solution.
One hour and fifty minutes following induction, the nitrous oxide was discontinued and oxygen 6 litres per minute was administered. Enflurane was ceased approximately 15 minutes prior to this. Reversal of neuromuscular blockade was accomplished with neostigmine 2.5 mg and atropine 1.2 mg. The patient began to show signs of arousal; he began moving his arms, reacted to the tube, had a positive lash reflex, and exhibited a good tidal volume. Ninety seconds pnor to extubation, lignocaine 1.0 mg/kg was administered. The oropharynx was carefully suctioned and the throat pack removed. Following laryngoscopic inspection of the oropharynx, the endotracheal tube was removed with positive pressure applied. Laryngospasm occurred after extubation, and because of the difficulty of oxygenating the patient by mask with the Levant frame in position, the patient was immediately reintubated with succinylcholine 100 mg and cricoid pressure. Intubation was accomplished easily, and the nasopharynx was noted to be dry. Ten minutes later the patient had resumed spontaneous respiration. At this stage, his heart rate was 90 beats per minute and blood pressure 130/80 mmHg. After a further ten minutes, although the tidal volumes were adequate, because the conscious state was still depressed in association with pinpoint pupils, naloxone 0.2 mg IV was administered. Following this, he was extubated when awake, and breathed well with a Guedel airway still in situ.
Approximately 30 seconds after extubation, and within 60 seconds of administration of naloxone, the patient suddenly started coughing up large volumes of pink frothy sputum characteristic of pulmonary oedema fluid. He was rapidly intubated with succinylcholine 100 mg, and intermittent positive pressure ventilation with positive end-expiratory pressure with 100% oxygen was instituted. He developed a profound bradycardia and cyanosis and unrecordable blood pressure. Resuscitation was commenced and atropine, adrenaline and calcium gluconate were given intravenously. Closed chest massage was commenced. Despite protracted resuscitative measures, the patient failed to respond, and was pronounced dead. Post mortem findings were partial collapse of the left upper lobe with some surgical emphysema and the presence of pulmonary oedema. There were no abnormalities of the brain or heart.
DISCUSSION
Pulmonary oedema is a recognised complication of acute upper airway obstruction, particularly in the paediatric population,4.5 although it has also been reported in adults. 6 ,7 In our patient, the laryngospasm was rapidly relieved by intubation before the onset of cyanosis. The pulmonary oedema was obvious within 60 seconds of IV administration of 0.2 mg of naloxone. Negative pressure pulmonary oedema secondary to partial upper airway obstruction was thought to be most unlikely.
Six cases of pulmonary oedema following naloxone administration have been reported in healthy patients. 8 -12 One of these was fatal. The mechanism of this response is unclear. Significant increases in cardiac work have been shown following narcotic reversal with naloxone. [13] [14] [15] These authors concluded that a reduced dosage regimen should be adopted for naloxone use. However, Prough et al. lo reported the occurrence of pulmonary oedema in two patients given 0.1 mg doses of naloxone. Pulmonary oedema has also been reported following 0.04-0.08 mg incremental doses of naloxone, 8 and a healthy young patient given 0.08 mg of naloxone subsequently required intubation. I I Tanaka l6 and Michaelis I reporting the occurrence of hypertension and ventricular irritability following naloxone administration, indicate that its use should be carefully appraised in patients with compromised cardiac function. Pinnock and Smith 17 commenting on the work of Peters et al. l .8 indicate that in hypotensive states in animal models, naloxone increases arterial pressure in both endotoxic and hypovolaemic shock. Weisglass l9 has shown that naloxone does not produce its effect by direct myocardial action, and has proposed that naloxone has the following actions on the circulation:
Centrally mediated increase in sympathetic
tone. This has also been suggested by others. 8 ,20,21 2. Central inhibition of parasympathetic output. 3. Peripheral antagonism of opioid peptides released in shock states. 4. A cellular action of stabilisation of lysosomes.
As opioid receptor chemistry is further understood, the causes of such reactions to naloxone may become apparent and more specific receptor antagonists may be developed.
Although the indications for naloxone in this case can be questioned, it was felt at the time that the depressed conscious state was due to persisting opioid effect, and that reversal was indicated. The bradycardia may have been due to a second dose of succinylcholine given approximately 22 minutes after the preceding dose, but should certainly have responded to the administration of atropine and adrenaline intravenously. Also, the pulmonary oedema appeared prior to the bradycardia, suggesting that the aetiology was more likely to be hypoxaemia.
In summary (Table 1) , the occurrence of pulmonary oedema following naloxone administration is a rare but significant problem which is not understood. It is still uncertain how to administer naloxone so as to avoid the complication of pulmonary oedema in a small subgroup of patients. At the present time, the only way of avoiding this complication is not to give naloxone. 
